Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP 1, Growth Hormone), and Mode of Purchase (Retail, Non-Retail) - Global Forecast to 2026
[223 Pages Report] The pen needles market is expected to reach USD 2.2 Billion by 2026 from an estimated USD 1.3 billion in 2021, at a CAGR of 11.2%. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug delivery, poor reimbursement in developing countries, and needle anxiety are expected to restrain the overall market growth. Misuse of insulin pens and reuse of pen needles are the challenges faced by the market. The growing preference for biosimilar drugs and emerging markets are areas of opportunity in the market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on Global Pen Needles Market
Type 2 diabetes, hypertension, and CVD significantly increase the risk for hospitalization and death in COVID-19 patients. Hence, managing these comorbidities has gained more focus for patients with existing conditions and those at the highest risk of contracting these conditions. This awareness has increased among healthcare professionals and patients and supported the growth of the management devices market. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. Optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients. Customized therapies for diabetes treatment have become necessary for rigorous glucose monitoring and insulin or anti-diabetic drug dose adjustments. The adoption of insulin pens, insulin pumps, and continuous glucose monitoring devices has been increased for close monitoring and optimal management of diabetes. Pen needles are used in great quantities in diabetes management. So these would naturally be impacted by any change in overall product and service demand.
PEN NEEDLES MARKET DYNAMICS
Driver: Growing prevalence of chronic diseases
The prevalence of chronic diseases has increased significantly in the last few years. Such diseases-including diabetes, osteoporosis, cardiovascular disease (CVD), and multiple sclerosis-require daily or weekly drug administration, typically using pen injectors. In the rapidly growing market, pen injectors have become the new standard for injectable drug delivery systems. Their popularity has soared due to their simplicity, reliability, and ability to be administered directly by the patient without the aid of a physician. The pen needle, a removable attachment, forms an integral part of the pen injector. The length of the needle and its sharpness is critical to ensure that the medication reaches the target tissues. Thus, the growing prevalence of chronic diseases has led to a greater focus on pen needle technologies to effectively handle the growing patient pool and increase patient compliance with therapies.
Restraint: Preference for alternative modes of drug delivery
While pen needles are an easy, hassle-free mode of drug delivery, they are also associated with needlestick injuries and infections, hyperglycemia, and pain. Insulin pen therapy is seen to cause hyperglycemia in some patients, as the dose cannot be regulated. Hence, in Europe, there has been a shift in diabetes treatment, from insulin pens to insulin pumps, due to their ability to perform automated insulin suspension and decrease the risk of hypoglycemia. This is a major factor restricting market growth. Although needle-free drug delivery technologies have addressed this issue to an extent, their range of applications in therapeutic areas is limited.
Opportunity: Growing preference for biosimilar drugs
Biosimilars were introduced in 2006 by many pharmaceutical companies such as Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and JCR Pharmaceuticals Co., Ltd. (Japan). Due to their lower costs (compared to their patented counterparts), the demand for biosimilars has increased significantly. In addition, the impending patent expiry of many biologic molecules will also serve to drive the demand for biosimilars.
Even insurance companies and governments are favoring the use of biosimilars and generics. For instance, CVS Caremark, a major prescription insurer in the US, has replaced branded injectable drugs such as Lantus by Sanofi and EpiPen by Mylan with their biosimilars Basaglar (available in injection pen) by Eli Lilly and Adrenaclick (an autoinjector) by Amedra Pharmaceuticals. This favors the pen needles market as Basaglar is administered via pen injector. Many other injectable drugs also rely on pen injection; thus, the growing preference for biosimilar drugs and support from governments and insurance providers will ensure strong opportunities for growth in this market.
Challenge: Reuse in pen needles
Needle reuse is a common practice in several parts of the world, with the extent of reuse of pen needles varying across geographies from as low as 30% to a staggering 95% of patients reusing their needles. According to a study published in Value Health Journal, about 98.35% of patients reuse insulin pen needles in China.
The most common reasons for this are unaffordability, lack of or no reimbursements in many developing countries, and convenience. The reuse of pen needles is a leading factor challenging market growth, as this curtails the demand for new needles. Furthermore, a study conducted by the Moscow Regional Research Clinical Institute found that bacteria were present on pen needles post-use and that bacterial growth on needles increased with further reuse. Reusing a pen needle can lead to multiple complications such as poor glycemic control, infection, and lipohypertrophy, indicating safety concerns tied to needle reuse.
North America is expected to account for the largest share of the pen needles market in 2020
North America dominated the pen needles market. The growing diabetes prevalence and favorable reimbursement scenario for pen needles, federal initiatives to create awareness about injection techniques, increasing market penetration by leading players, and the development of improved pen needle technologies are driving market growth in the US.
Key Market Players
Prominent players in the pen needles market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Owen Mumford (UK), Terumo Corporation (Japan), Nipro Corporation (Japan) Allison Medical (US), AdvaCare Pharma (US), Berpu Medical Technology (China), ARKRAY (Japan), GlucoRx (UK), HTL-STREFA (Poland), UltiMed, (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Diabetes Care (Canada), Montmed (Canada), Trividia Health (US), VOGT Medical Vertrieb (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), Iyon (Turkey), Links Medical Products (US), and MHC Medical Products (US).
Scope of the report
|
Report Metric |
Details |
|
Market size available for years |
20192026 |
|
Base year considered |
2020 |
|
Forecast period |
20212026 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
By type, length, mode of purchase and therapy |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Owen Mumford (UK), Terumo Corporation (Japan), Nipro Corporation (Japan) Allison Medical (US), AdvaCare Pharma (US), Berpu Medical Technology (China), ARKRAY (Japan), GlucoRx (UK), HTL-STREFA (Poland), UltiMed, (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Diabetes Care (Canada), Montmed (Canada), Trividia Health (US), VOGT Medical Vertrieb (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), Iyon (Turkey), Links Medical Products (US), and MHC Medical Products (US). |
The study categorizes the Pen Needles Market based on type, therapy, mode of purchase, length and regional and global level.
Global pen needles market, by product type
- Standard pen needles
- Safety pen needles
Global pen needles market, by length
- 4mm
- 5mm
- 6mm
- 8mm
- 10mm
- 12mm
Global pen needles market, by therapy
- Insulin therapy
- Glucagon-like Peptide-1 (GLP-1) therapy
- Growth hormone therapy
- Other therapies
Global pen needles market, by mode of purchase
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- JapanAustralia and New Zealand
- South Korea
- South East Asia
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In February 2021, Ulticare safety pen needles are launched in two sizes, 5mm 30G and 8mm 30 G launched by UltiMed Inc. (US).
- In October 2020, Arkray Inc. (Japan) launched TechLITE Pen Needles which are now indicated for use with pen injector devices for the subcutaneous injection of drugs in the US.
- In January 2019, Becton, Dickinson and Company (US) launched Second Generation Standard Pen Needles.
- In August 2018, Arkray Inc. (Japan) launched Assure ID safety pen needles.
Frequently Asked Questions (FAQ):
Which are the top industry players in the global pen needles market?
Some of the major players in the pen needles market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Owen Mumford (UK), Terumo Corporation (Japan), Nipro Corporation (Japan) Allison Medical (US), AdvaCare Pharma (US), Berpu Medical Technology (China), ARKRAY (Japan), GlucoRx (UK), HTL-STREFA (Poland), UltiMed, (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Diabetes Care (Canada), Montmed (Canada), Trividia Health (US), VOGT Medical Vertrieb (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), Iyon (Turkey), Links Medical Products (US), and MHC Medical Products (US).
Which geographical region is dominating in the global pen needles market?
North America dominated the pen needles market. The growing diabetes prevalence and favorable reimbursement scenario for pen needles, federal initiatives to create awareness about injection techniques, increasing market penetration by leading players, and the development of improved pen needle technologies are driving market growth in the US.
Which is the leading product by type segment in pen needles market?
Based on the type of product, the pen needle market is segmented into standard pen needles and safety pen needles. Standard pen needles are preferred over safety pen needles as they are more affordable, especially considering the need for daily insulin intake. The low cost of standard pen needles has also led to their wide adoption in emerging economies.
Which is the highest growing therapy segment in pen needles market?
Based on therapy, the market is categorized into insulin therapy, glucagon-like peptide-1 (GLP-1) therapy, growth hormone therapy, and other therapies (osteoporosis, obesity, thyroid). In 2020, insulin therapy held the highest share of the global pen needles market, primarily due to the high and growing diabetic population globally. This segment is also expected to grow at the highest rate during the forecast period.
Which is the highest growing segment by length in pen needles market?
Based on length, the market is segmented into 4mm (5/32), 5mm (3/16), 6mm (1/4), 8mm (5/16), 10mm, and 12mm (1/2). In 2020, the 8mm segment accounted for the largest share in the pen needles market. The large share of this segment is mainly attributed to the wide adoption of these needles among diabetes patients. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.3.1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (PEN NEEDLES MARKET)
2.2 MARKET SIZE ESTIMATION
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: BECTON, DICKINSON AND COMPANY (2020)
FIGURE 7 REVENUE ANALYSIS OF THE TOP FIVE COMPANIES: PEN NEEDLES MARKET (2020)
FIGURE 8 DEMAND-SIDE ANALYSIS
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE PEN NEEDLES MARKET (20212026)
FIGURE 11 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: PEN NEEDLES MARKET
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 13 PEN NEEDLES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 14 PEN NEEDLES MARKET, BY LENGTH, 2021 VS. 2026 (USD MILLION)
FIGURE 15 PEN NEEDLES MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
FIGURE 16 PEN NEEDLES MARKET, BY MODE OF PURCHASE, 2021 VS. 2026 (USD MILLION)
FIGURE 17 GEOGRAPHIC SNAPSHOT: PEN NEEDLES MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 PEN NEEDLES MARKET OVERVIEW
FIGURE 18 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE PEN NEEDLES MARKET
4.2 ASIA PACIFIC: PEN NEEDLES MARKET, BY THERAPY AND COUNTRY
FIGURE 19 JAPAN DOMINATES THE APAC MARKET
4.3 PEN NEEDLES MARKET: GEOGRAPHIC MIX
FIGURE 20 INDIA & CHINA TO WITNESS THE HIGHEST GROWTH IN THE PEN NEEDLES MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 PEN NEEDLES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of chronic diseases
FIGURE 22 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN THE US, 19952030 (MILLION INDIVIDUALS)
FIGURE 23 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
5.2.1.2 Favorable reimbursement in select countries
5.2.2 RESTRAINTS
5.2.2.1 Preference for alternative modes of drug delivery
5.2.2.2 Poor reimbursement scenario in developing countries
5.2.2.3 Needle anxiety
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for biosimilar drugs
5.2.3.2 Emerging markets
TABLE 2 RISING INCOME LEVELS IN EMERGING COUNTRIES
5.2.4 CHALLENGES
5.2.4.1 Reuse of pen needles
5.2.4.2 Misuse of injection pens
5.3 PRICING ANALYSIS
TABLE 3 PRICING OF PEN NEEDLES AVAILABLE IN THE MARKET
5.4 VALUE CHAIN ANALYSIS
FIGURE 24 PEN NEEDLES MARKET: VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
FIGURE 25 PEN NEEDLES MARKET: ECOSYSTEM MARKET MAP
5.6 PORTERS FIVE FORCES ANALYSIS
TABLE 4 PEN NEEDLES MARKET: PORTERS FIVE FORCES ANALYSIS
5.6.1 INTENSITY OF COMPETITIVE RIVALRY
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 THREAT OF NEW ENTRANTS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 26 PEN NEEDLES MARKET: SUPPLY CHAIN ANALYSIS
5.8 REGULATORY ANALYSIS
5.8.1 NORTH AMERICA
5.8.1.1 US
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.8.1.2 Canada
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 27 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS
5.8.2 EUROPE
FIGURE 28 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES
5.8.3 ASIA PACIFIC
5.8.3.1 Japan
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.8.3.2 China
TABLE 9 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL
TABLE 10 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.8.3.3 India
5.9 IMPACT OF COVID-19 ON THE PEN NEEDLES MARKET
5.10 PATENT ANALYSIS
5.10.1 PATENT PUBLICATION TRENDS FOR PEN NEEDLES
FIGURE 29 PATENT PUBLICATION TRENDS (2011MAY 2021)
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PEN NEEDLES PATENTS (JANUARY 2011JUNE 2021)
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR PEN NEEDLE PATENTS (JANUARY 2011JUNE 2021)
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGY
5.11.1.1 Fluid flow enhancement technology
5.11.2 COMPLEMENTARY TECHNOLOGY
5.11.2.1 Microfabricated needles
5.11.3 ADJACENT TECHNOLOGY
5.11.3.1 Autoinjectors
6 PEN NEEDLES MARKET, BY TYPE (Page No. - 73)
6.1 INTRODUCTION
TABLE 11 PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 12 PEN NEEDLES MARKET, BY TYPE, 20192026 (MILLION UNITS)
6.2 STANDARD PEN NEEDLES
6.2.1 STANDARD PEN NEEDLES ARE PREFERRED OVER SAFETY PEN NEEDLES AS THEY ARE MORE AFFORDABLE
TABLE 13 STANDARD PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 14 STANDARD PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 15 STANDARD PEN NEEDLES MARKET, BY COUNTRY, 20192026 (MILLION UNITS)
6.3 SAFETY PEN NEEDLES
6.3.1 GROWING CONCERN OVER NEEDLESTICK INJURIES DRIVES THE GROWTH OF SAFETY PEN NEEDLES
TABLE 16 SAFETY PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 17 SAFETY PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 18 SAFETY PEN NEEDLES MARKET, BY COUNTRY, 20192026 (MILLION UNITS)
7 PEN NEEDLES MARKET, BY LENGTH (Page No. - 80)
7.1 INTRODUCTION
TABLE 19 PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
7.2 8MM
7.2.1 8MM PEN NEEDLES WILL CONTINUE TO DOMINATE THE PEN NEEDLES MARKET DURING THE FORECAST PERIOD
TABLE 20 8MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 21 8MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
7.3 5MM
7.3.1 5MM PEN NEEDLES TO REGISTER SECOND-HIGHEST GROWTH RATE DURING THE STUDY PERIOD
TABLE 22 5MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 23 5MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
7.4 6MM
7.4.1 6MM PEN NEEDLES ARE THE MOST COMMONLY USED NEEDLES ACROSS THE GLOBE
TABLE 24 6MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 25 6MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
7.5 4MM
7.5.1 4MM PEN NEEDLES ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
TABLE 26 4MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 27 4MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
7.6 12MM
7.6.1 THE POPULARITY OF SHORTER & LESS PAINFUL NEEDLES HAMPERS THE GROWTH OF THE 12MM PEN NEEDLES MARKET
TABLE 28 12MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 29 12MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
7.7 10MM
7.7.1 AVAILABILITY OF SHORTER PEN NEEDLES TO RESTRAIN THE GROWTH OF THE 10MM PEN NEEDLES MARKET
TABLE 30 10MM PEN NEEDLES OFFERED BY KEY PLAYERS
TABLE 31 10MM PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
8 PEN NEEDLES MARKET, BY THERAPY (Page No. - 91)
8.1 INTRODUCTION
TABLE 32 PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
8.2 INSULIN THERAPY
8.2.1 RISING PREVALENCE OF DIABETES DRIVES THE GROWTH OF THE PEN NEEDLES MARKET FOR INSULIN THERAPY
TABLE 33 PEN NEEDLES MARKET FOR INSULIN THERAPY, BY COUNTRY, 20192026 (USD MILLION)
8.3 GLUCAGON-LIKE PEPTIDE-1 THERAPY
8.3.1 STRONG FOCUS OF MAJOR PHARMACEUTICAL COMPANIES TO INTRODUCE GLP-1 DRUGS TO DRIVE MARKET GROWTH
TABLE 34 PEN NEEDLES MARKET FOR GLP-1 THERAPY, BY COUNTRY, 20192026 (USD MILLION)
8.4 GROWTH HORMONE THERAPY
8.4.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE GROWTH OF THE PEN NEEDLES MARKET FOR GROWTH HORMONE THERAPY
TABLE 35 PEN NEEDLES MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 20192026 (USD MILLION)
8.5 OTHER THERAPIES
TABLE 36 PEN NEEDLES MARKET FOR OTHER THERAPIES, BY COUNTRY, 20192026 (USD MILLION)
9 PEN NEEDLES MARKET, BY MODE OF PURCHASE (Page No. - 98)
9.1 INTRODUCTION
TABLE 37 PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
9.2 RETAIL
9.2.1 RETAIL PURCHASES OF PEN NEEDLES TO WITNESS HIGH GROWTH IN THE COMING YEARS OWING TO THE GROWING POPULARITY OF ONLINE PURCHASES
TABLE 38 PEN NEEDLES MARKET FOR RETAIL PURCHASES, BY COUNTRY, 20192026 (USD MILLION)
9.3 NON-RETAIL
9.3.1 LARGE NUMBER OF NEEDLE-PHOBIC DIABETIC PATIENTS IS SUPPORTING THE GROWTH OF THIS SEGMENT
TABLE 39 INDICATIVE LIST OF REGULATIONS
TABLE 40 PEN NEEDLES MARKET FOR NON-RETAIL PURCHASES, BY COUNTRY, 20192026 (USD MILLION)
10 PEN NEEDLES MARKET, BY REGION (Page No. - 103)
10.1 INTRODUCTION
TABLE 41 PEN NEEDLES MARKET, BY REGION, 20192026 (USD MILLION)
FIGURE 32 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH OVER THE FORECAST PERIOD
10.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: PEN NEEDLES MARKET SNAPSHOT
TABLE 42 NORTH AMERICA: PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 43 NORTH AMERICA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 44 NORTH AMERICA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 45 NORTH AMERICA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 46 NORTH AMERICA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the global pen needles market
FIGURE 34 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)
TABLE 47 US: KEY MACROINDICATORS
TABLE 48 US: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 49 US: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 50 US: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 51 US: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth
TABLE 52 CANADA: KEY MACROINDICATORS
TABLE 53 CANADA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 54 CANADA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 55 CANADA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 56 CANADA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3 EUROPE
TABLE 57 EUROPE: PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 58 EUROPE: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 59 EUROPE: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 60 EUROPE: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 61 EUROPE: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 High diabetes expenditure and reimbursement for pen needles is expected to drive the market in Germany
TABLE 62 GERMANY: KEY MACROINDICATORS
TABLE 63 GERMANY: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 64 GERMANY: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 65 GERMANY: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 66 GERMANY: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Favorable health insurance system to drive the pen needles market in France
TABLE 67 FRANCE: KEY MACROINDICATORS
TABLE 68 FRANCE: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 69 FRANCE: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 70 FRANCE: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 71 FRANCE: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION) 20192026 (USD MILLION) 120
10.3.3 UK
10.3.3.1 NHS support and access to cost-effective pen needles are likely to drive the market in the UK
TABLE 72 UK: KEY MACROINDICATORS
TABLE 73 UK: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 74 UK: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 75 UK: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 76 UK: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth
TABLE 77 ITALY: KEY MACROINDICATORS
TABLE 78 ITALY: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 79 ITALY: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 80 ITALY: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 81 ITALY: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Supportive regulations mandating the use of safety pen needles to boost the growth of the Spanish market
TABLE 82 SPAIN: KEY MACROINDICATORS
TABLE 83 SPAIN: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 84 SPAIN: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 85 SPAIN: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 86 SPAIN: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 87 ROE: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 88 ROE: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 89 ROE: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 90 ROE: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 35 APAC: PEN NEEDLES MARKET SNAPSHOT
TABLE 91 APAC: PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 92 APAC: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 93 APAC: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 94 APAC: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 95 APAC: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan
TABLE 96 JAPAN: KEY MACROINDICATORS
TABLE 97 JAPAN: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 98 JAPAN: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 99 JAPAN: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 100 JAPAN: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China
TABLE 101 CHINA: KEY MACROINDICATORS
TABLE 102 CHINA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 103 CHINA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 104 CHINA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 105 CHINA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.3 AUSTRALIA AND NEW ZEALAND
10.4.3.1 Growing geriatric population in Australia and New Zealand to drive the pen needles market
TABLE 106 AUSTRALIA AND NEW ZEALAND: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 107 AUSTRALIA AND NEW ZEALAND: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 108 AUSTRALIA AND NEW ZEALAND: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 109 AUSTRALIA AND NEW ZEALAND: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Healthcare infrastructural improvements and implementation of favorable government initiatives support the market in India
TABLE 110 INDIA: KEY MACROINDICATORS
TABLE 111 INDIA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 112 INDIA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 113 INDIA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 114 INDIA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Growing chronic diseases in the geriatric population augments the growth of the pen needles market
TABLE 115 SOUTH KOREA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 116 SOUTH KOREA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 117 SOUTH KOREA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 118 SOUTH KOREA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.6 SOUTHEAST ASIA
10.4.6.1 Growing awareness about diabetes drives the pen needles market
FIGURE 36 GROWING PREVALENCE OF DIABETES IN SOUTHEAST ASIA
FIGURE 37 HEALTHCARE EXPENDITURE (% GDP) IN SOUTHEAST ASIA (2018)
FIGURE 38 GERIATRIC POPULATION IN 2019 (% OF TOTAL POPULATION)
TABLE 119 SOUTHEAST ASIA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 120 SOUTHEAST ASIA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 121 SOUTHEAST ASIA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 122 SOUTHEAST ASIA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.4.7 REST OF APAC
TABLE 123 ROAPAC: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 124 ROAPAC: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 125 ROAPAC: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 126 ROAPAC: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 127 LATIN AMERICA: PEN NEEDLES MARKET, BY COUNTRY, 20192026 (USD MILLION)
TABLE 128 LATIN AMERICA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 129 LATIN AMERICA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 130 LATIN AMERICA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 131 LATIN AMERICA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil dominates the pen needles market in Latin America
TABLE 132 BRAZIL: KEY MACROINDICATORS
TABLE 133 BRAZIL: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 134 BRAZIL: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 135 BRAZIL: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 136 BRAZIL: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Increasing incidence of lifestyle-related disorders and rising awareness drive market growth in Mexico
TABLE 137 MEXICO: KEY MACROINDICATORS
TABLE 138 MEXICO: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 139 MEXICO: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 140 MEXICO: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 141 MEXICO: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
FIGURE 39 HEALTH EXPENDITURE IN LATIN AMERICAN COUNTRIES IN 2018 (% GDP)
TABLE 142 ROLA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 143 ROLA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 144 ROLA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 145 ROLA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
10.6 MIDDLE EAST AND AFRICA
10.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY MAY SUPPORT MARKET GROWTH
TABLE 146 MEA: PEN NEEDLES MARKET, BY TYPE, 20192026 (USD MILLION)
TABLE 147 MEA: PEN NEEDLES MARKET, BY LENGTH, 20192026 (USD MILLION)
TABLE 148 MEA: PEN NEEDLES MARKET, BY THERAPY, 20192026 (USD MILLION)
TABLE 149 MEA: PEN NEEDLES MARKET, BY MODE OF PURCHASE, 20192026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 155)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 40 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE PEN NEEDLES MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 41 PEN NEEDLES MARKET SHARE, BY KEY PLAYER, 2020
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 42 PEN NEEDLES MARKET: COMPANY EVALUATION QUADRANT (2020)
11.6 COMPANY EVALUATION QUADRANT FOR START-UPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 DYNAMIC COMPANIES
11.6.3 STARTING BLOCKS
11.6.4 RESPONSIVE COMPANIES
FIGURE 43 PEN NEEDLES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)
11.7 COMPANY PRODUCT FOOTPRINT
TABLE 150 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES MARKET
TABLE 151 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES MARKET, BY LENGTH
TABLE 152 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES MARKET, BY THERAPY
11.8 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 153 GEOGRAPHIC REVENUE MIX: PEN NEEDLES MARKET (2020)
11.9 COMPETITIVE INTENSITY
11.9.1 EVALUATION PARAMETERS
TABLE 154 EVALUATION PARAMETERS & SCORES
11.9.2 SCORING METHODOLOGY FOR COMPETITIVE INTENSITY
FIGURE 44 SCORING METHODOLOGY FOR COMPETITIVE INTENSITY
11.9.3 COMPETITIVE INTENSITY SCORE, BY COMPANY
11.9.3.1 Competitive intensity score for BD
TABLE 155 COMPETITIVE INTENSITY FOR BD
11.9.3.2 Competitive intensity score for Novo Nordisk
TABLE 156 COMPETITIVE INTENSITY FOR NOVO NORDISK
11.9.3.3 Competitive intensity score for Ypsomed
TABLE 157 COMPETITIVE INTENSITY FOR YPSOMED
11.9.4 COMPETITIVE INTENSITY MAPPING: BD, NOVO NORDISK, AND YPSOMED
FIGURE 45 COMPARISONS OF COMPETITIVE INTENSITY SCORES: BD, NOVO NORDISK, AND YPSOMED
FIGURE 46 RELATIVE POSITIONING OF COMPANIES BASED ON COMPETITIVE INTENSITY SCORE AND PEN NEEDLE FOCUS
11.9.4.1 Product launches/technological advancements
FIGURE 47 BD HAS A HIGHER FOCUS ON INNOVATION FOR ITS PEN NEEDLES BUSINESS
11.9.4.2 Promotional/marketing activities
FIGURE 48 BD AND NOVO NORDISK SHOWCASE A HIGH FOCUS ON MARKETING & PROMOTIONAL ACTIVITIES
11.9.4.3 Sponsorships/donations/education/awareness campaigns
FIGURE 49 NOVO NORDISK A/S HAS A HIGH FOCUS ON DIABETES EDUCATION & AWARENESS
11.9.4.4 Certifications/accreditations/awards
FIGURE 50 BD, NOVO NORDISK, AND YPSOMED EQUALLY EXHIBIT HIGH COMPLIANCE WITH INDUSTRY STANDARDS
11.1 COMPETITIVE SCENARIO
11.10.1 PRODUCT LAUNCHES
TABLE 158 PRODUCT LAUNCHES (JANUARY 2018 JUNE 2021)
11.10.2 DEALS
TABLE 159 DEALS (JANUARY 2018 JUNE 2021)
11.10.3 OTHER DEVELOPMENTS
TABLE 160 OTHER DEVELOPMENTS (JANUARY 2018 JUNE 2021)
12 COMPANY PROFILES (Page No. - 177)
12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MNM view)*
12.1.1 BECTON, DICKINSON AND COMPANY
TABLE 161 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.1.2 NOVO NORDISK A/S
TABLE 162 NOVO NORDISK A/S: BUSINESS OVERVIEW
FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)
12.1.3 YPSOMED HOLDING AG
TABLE 163 YPSOMED HOLDING AG: BUSINESS OVERVIEW
FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)
12.1.4 B. BRAUN MELSUNGEN AG
TABLE 164 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 54 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2020)
12.1.5 TERUMO CORPORATION
TABLE 165 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 55 TERUMO CORPORATION: COMPANY SNAPSHOT (2020)
12.1.6 NIPRO CORPORATION
TABLE 166 NIPRO CORPORATION: BUSINESS OVERVIEW
FIGURE 56 NIPRO CORPORATION: COMPANY SNAPSHOT (2020)
12.1.7 OWEN MUMFORD
TABLE 167 OWEN MUMFORD: BUSINESS OVERVIEW
12.1.8 ARKRAY
TABLE 168 ARKRAY: BUSINESS OVERVIEW
12.1.9 ULTIMED
TABLE 169 ULTIMED: BUSINESS OVERVIEW
12.1.10 HINDUSTAN SYRINGES AND MEDICAL DEVICES
TABLE 170 HINDUSTAN SYRINGES AND MEDICAL DEVICES: BUSINESS OVERVIEW
12.1.11 MONTMED
TABLE 171 MONTMED: BUSINESS OVERVIEW
12.1.12 HTL-STREFA
TABLE 172 HTL-STREFA: BUSINESS OVERVIEW
12.1.13 ALLISON MEDICAL, INC.
TABLE 173 ALLISON MEDICAL: BUSINESS OVERVIEW
12.1.14 GLUCORX
TABLE 174 GLUCORX: BUSINESS OVERVIEW
12.1.15 BERPU MEDICAL TECHNOLOGY
TABLE 175 BERPU MEDICAL TECHNOLOGY: BUSINESS OVERVIEW
12.1.16 ADVACARE PHARMA
TABLE 176 ADVACARE PHARMA: BUSINESS OVERVIEW
12.1.17 ARTSANA GROUP
TABLE 177 ARTSANA GROUP: BUSINESS OVERVIEW
12.1.18 PROMISEMED DIABETES CARE
TABLE 178 PROMISEMED DIABETES CARE: BUSINESS OVERVIEW
12.1.19 TRIVIDIA HEALTH
TABLE 179 TRIVIDIA HEALTH: BUSINESS OVERVIEW
12.1.20 VOGT MEDICAL VERTRIEB
TABLE 180 VOGT MEDICAL VERTRIEB GMBH: BUSINESS OVERVIEW
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 VAN HEEK MEDICAL
TABLE 181 VAN HEEK MEDICAL: COMPANY OVERVIEW
12.2.2 SIMPLE DIAGNOSTICS
TABLE 182 SIMPLE DIAGNOSTICS: COMPANY OVERVIEW
12.2.3 IYON
TABLE 183 IYON: COMPANY OVERVIEW
12.2.4 LINKS MEDICAL PRODUCTS
TABLE 184 LINKS MEDICAL PRODUCTS: COMPANY OVERVIEW
12.2.5 MHC MEDICAL PRODUCTS
TABLE 185 MHC MEDICAL PRODUCTS: COMPANY OVERVIEW
13 APPENDIX (Page No. - 216)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the pen needles market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the pen needles market was arrived at after data triangulation from four different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this reports market engineering process.
Objectives of the Study
- To validate the segmentation defined through the assessment of the product portfolios of the leading players in the market
- To understand key industry trends and issues defining the growth objectives of market players
- To gather both demand- and supply-side validation of the key factors affecting market growth, including market drivers, restraints, opportunities, and challenges
- To validate assumptions for the market sizing and forecasting model used for this market study
- To understand the market positions of the leading players in the pen needles market and their shares/rankings
- To understand the ongoing pricing trends in the market and future expectations
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your companys specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the RoE pen needles market into Belgium, Russia, the Netherlands, Switzerland, and others.
- Further breakdown of the RoAPAC pen needles market into Pakistan, Myanmar, Bangladesh and Cambodia.
- Further breakdown of the RoLA pen needles market into Argentina, Chile, Peru, Ecuador, Colombia, Uruguay, Bolivia, and Venezuela.
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies
Get in-depth analysis of the COVID-19 impact on the Pen Needles Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Pen Needles Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Pen Needles Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Pen Needles Market
how about Owen Mumford pen needle market? any chance their able grow more than others?